Effects of Trabectedine on tumour growth and metabolism in preclinical models of HER-2 overexpressing ovarian cancer
Egidio Iorio 1 , Fabio Ginnari Satriani 1 , Alessandro Ricci 1 , Emiliano Surrentino 1 , Marina Bagnoli 2 , Paola Alberti 2 , Franca Podo 1 , Delia Mezzanzanica 2 , and Rossella Canese 1
Cell Biology and Neurosciences Dept,
Istituto Superiore di Sanit, Rome, Italy,
Oncology Dept, Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan, Italy
Epithelial ovarian cancer (EOC) is a heterogeneous
disease with a poor prognosis. Evaluation of metabolic
effects of anticancer therapies would enhance the
capability of non invasive imaging approaches to monitor
molecular mechanisms underlying tumour responsiveness.
Here we explore the role of MRI/MRS in the detection of
the cytotoxic response of trabectedin (ET-743, a new
marine-derived antitumor agent, which has shown in vitro
and in vivo activity in ovarian cancer) in experimental
EOC models, showing previously unexplored trabectedine-induced
metabolic and morphofunctional changes.
This abstract and the presentation materials are available to members only;
a login is required.